ARGNF News and Press, Argen X NV From 07/16/22

Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. We are closely watching corporate results to determine the near-term outlook for international equities. How co...

Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shar...

The following slide deck was published by argenx SE in conjunction with this event. For further details see: argenx SE - ADR (ARGX) Investor Presentation - Slideshow

The following slide deck was published by argenx SE in conjunction with their 2022 Q1 earnings call. For further details see: argenx SE 2022 Q1 - Results - Earnings Call Presentation

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

argenx SE (ARGX) Q4 2021 Earnings Conference Call March 03, 2022 08:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations and Corporate Communications Tim Van Hauwermeiren - Chief Executive Officer Keith Woods - Chief Operating Officer Karl Gubitz - Chief Financial...

The following slide deck was published by argenx SE in conjunction with their 2021 Q4 earnings call. For further details see: argenx SE 2021 Q4 - Results - Earnings Call Presentation

Plans to initiate phase 3 study using batoclimab for the treatment of patients with myasthenia gravis expected 1st half of 2022. Two additional indications in the pipeline will be announced in August of 2022. Goal to choose two additional indications with the use of batoclimab to ...